181 related articles for article (PubMed ID: 26025562)
1. Changes in cognitive symptoms after a buspirone-melatonin combination treatment for Major Depressive Disorder.
Targum SD; Wedel PC; Fava M
J Psychiatr Res; 2015 Sep; 68():392-6. PubMed ID: 26025562
[TBL] [Abstract][Full Text] [Related]
2. An exploratory study of combination buspirone and melatonin SR in major depressive disorder (MDD): a possible role for neurogenesis in drug discovery.
Fava M; Targum SD; Nierenberg AA; Bleicher LS; Carter TA; Wedel PC; Hen R; Gage FH; Barlow C
J Psychiatr Res; 2012 Dec; 46(12):1553-63. PubMed ID: 22998742
[TBL] [Abstract][Full Text] [Related]
3. A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment.
Fava M; Graves LM; Benazzi F; Scalia MJ; Iosifescu DV; Alpert JE; Papakostas GI
J Clin Psychiatry; 2006 Nov; 67(11):1754-9. PubMed ID: 17196056
[TBL] [Abstract][Full Text] [Related]
4. A comparative analysis between site-based and centralized ratings and patient self-ratings in a clinical trial of Major Depressive Disorder.
Targum SD; Wedel PC; Robinson J; Daniel DG; Busner J; Bleicher LS; Rauh P; Barlow C
J Psychiatr Res; 2013 Jul; 47(7):944-54. PubMed ID: 23562150
[TBL] [Abstract][Full Text] [Related]
5. Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder.
Levkovitz Y; Alpert JE; Brintz CE; Mischoulon D; Papakostas GI
Eur Psychiatry; 2012 Oct; 27(7):518-21. PubMed ID: 21665441
[TBL] [Abstract][Full Text] [Related]
6. Is the Noradrenergic Symptom Cluster a Valid Construct in Adjunctive Treatment of Major Depressive Disorder?
Stauffer VL; Liu P; Goldberger C; Marangell LB; Nelson C; Gorwood P; Fava M
J Clin Psychiatry; 2017 Mar; 78(3):317-323. PubMed ID: 27685842
[TBL] [Abstract][Full Text] [Related]
7. A randomized double-blind placebo-controlled trial of treatment as usual plus exogenous slow-release melatonin (6 mg) or placebo for sleep disturbance and depressed mood.
Serfaty MA; Osborne D; Buszewicz MJ; Blizard R; Raven PW
Int Clin Psychopharmacol; 2010 May; 25(3):132-42. PubMed ID: 20195158
[TBL] [Abstract][Full Text] [Related]
8. Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder.
Levkovitz Y; Alpert JE; Brintz CE; Mischoulon D; Papakostas GI
J Affect Disord; 2012 Feb; 136(3):1174-8. PubMed ID: 21911258
[TBL] [Abstract][Full Text] [Related]
9. Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT(1A) receptor agonist.
Piskulić D; Olver JS; Maruff P; Norman TR
Hum Psychopharmacol; 2009 Aug; 24(6):437-46. PubMed ID: 19637398
[TBL] [Abstract][Full Text] [Related]
10. Chronobiology, cognitive function and depressive symptoms in surgical patients.
Hansen MV
Dan Med J; 2014 Sep; 61(9):B4914. PubMed ID: 25186550
[TBL] [Abstract][Full Text] [Related]
11. The relationship between change in apathy and changes in cognition and functional outcomes in currently non-depressed SSRI-treated patients with major depressive disorder.
Rothschild AJ; Raskin J; Wang CN; Marangell LB; Fava M
Compr Psychiatry; 2014 Jan; 55(1):1-10. PubMed ID: 24268564
[TBL] [Abstract][Full Text] [Related]
12. Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target.
Goeldner C; Ballard TM; Knoflach F; Wichmann J; Gatti S; Umbricht D
Neuropharmacology; 2013 Jan; 64():337-46. PubMed ID: 22992331
[TBL] [Abstract][Full Text] [Related]
13. What is the overlap between subjective and objective cognitive impairments in MDD?
Fava M; Mahableshwarkar AR; Jacobson W; Zhong W; Keefe RS; Olsen CK; Jaeger J
Ann Clin Psychiatry; 2018 Aug; 30(3):176-184. PubMed ID: 30028891
[TBL] [Abstract][Full Text] [Related]
14. Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study.
Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Hann D; Marangell LB
Curr Med Res Opin; 2011 Oct; 27(10):1859-67. PubMed ID: 21838410
[TBL] [Abstract][Full Text] [Related]
15. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study.
Sumiyoshi T; Park S; Jayathilake K; Roy A; Ertugrul A; Meltzer HY
Schizophr Res; 2007 Sep; 95(1-3):158-68. PubMed ID: 17628435
[TBL] [Abstract][Full Text] [Related]
16. Differentiating residual symptoms of depression from adverse events among patients initiating treatment with an antidepressant.
Freeman MP; Fisher L; Clain A; Rabbitt R; Pooley J; Baer L; Fava M
Ann Clin Psychiatry; 2017 Feb; 29(1):28-34. PubMed ID: 28207913
[TBL] [Abstract][Full Text] [Related]
17. Prolactin response to buspirone is not impaired in drug-naïve first episode patients with major depressive disorder.
Cubała WJ; Landowski J
J Affect Disord; 2014 Jan; 152-154():468-73. PubMed ID: 24035672
[TBL] [Abstract][Full Text] [Related]
18. Cognitive remission: a novel objective for the treatment of major depression?
Bortolato B; Miskowiak KW; Köhler CA; Maes M; Fernandes BS; Berk M; Carvalho AF
BMC Med; 2016 Jan; 14():9. PubMed ID: 26801406
[TBL] [Abstract][Full Text] [Related]
19. Neurocognitive performance, subjective well-being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add-on melatonin versus placebo.
Baandrup L; Fagerlund B; Glenthoj B
Eur Arch Psychiatry Clin Neurosci; 2017 Mar; 267(2):163-171. PubMed ID: 27400927
[TBL] [Abstract][Full Text] [Related]
20. Cognitive impairment in major depressive disorder.
Pan Z; Park C; Brietzke E; Zuckerman H; Rong C; Mansur RB; Fus D; Subramaniapillai M; Lee Y; McIntyre RS
CNS Spectr; 2019 Feb; 24(1):22-29. PubMed ID: 30468135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
